207 related articles for article (PubMed ID: 33204258)
1. Clinical Characteristics and Management of Functional Pancreatic Neuroendocrine Neoplasms: A Single Institution 20-Year Experience with 286 Patients.
Qu Y; Li H; Wang X; Chen Y; Guo Q; Pei Y; Du J; Dou J; Ba J; Lv Z; Mu Y
Int J Endocrinol; 2020; 2020():1030518. PubMed ID: 33204258
[TBL] [Abstract][Full Text] [Related]
2. An Insight on Functioning Pancreatic Neuroendocrine Neoplasms.
Bevere M; Gkountakos A; Martelli FM; Scarpa A; Luchini C; Simbolo M
Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830839
[TBL] [Abstract][Full Text] [Related]
3. [Comparison of clinical characteristics between sporadic gastrinoma and multiple endocrine neoplasia type 1-related gastrinoma].
Guo Y; Chen LH; Liu M; Zhang YX; Zhang N; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Oct; 24(10):875-882. PubMed ID: 34674462
[No Abstract] [Full Text] [Related]
4. [Surgical treatment of gastric, enteric, and pancreatic endocrine tumors Part 1. Treatment of primary endocrine tumors].
Kianmanesh R; O'toole D; Sauvanet A; Ruszniewski P; Belghiti J
J Chir (Paris); 2005; 142(3):132-49. PubMed ID: 16142076
[TBL] [Abstract][Full Text] [Related]
5. Natural history and clinical outcomes of pancreatic neuroendocrine neoplasms based on the WHO 2017 classification; a single-center experience of 30 years.
Fujimori N; Miki M; Lee L; Matsumoto K; Takamatsu Y; Takaoka T; Teramatsu K; Suehiro Y; Murakami M; Igarashi H; Oono T; Ohtsuka T; Nakamura M; Koga Y; Oda Y; Ito T; Ogawa Y
Pancreatology; 2020 Jun; 20(4):709-715. PubMed ID: 32360001
[TBL] [Abstract][Full Text] [Related]
6. The characteristics of serum lipid spectrum in PanNENs and its correlation with clinicopathological features and prognosis.
Meng YF; Fan ZY; Yang J; Li YZ; Liu SJ; Gao CH; Gao X; Pang CY; Zhan HX
Front Endocrinol (Lausanne); 2023; 14():1137911. PubMed ID: 37033225
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations.
Panzuto F; Pusceddu S; Faggiano A; Rinzivillo M; Brighi N; Prinzi N; Riccardi F; Iannicelli E; Maggio I; Femia D; Tafuto S; Manuzzi L; Di Sarno A; Annibale B; de Braud F; Campana D;
Pancreatology; 2019 Dec; 19(8):1067-1073. PubMed ID: 31587962
[TBL] [Abstract][Full Text] [Related]
8. [Clinicopathologic features and prognostic analysis of 240 patients with gastric neuroendocrine neoplasms].
Liang WQ; Zhang W; Qiao S; Wang BH; Wang C; Zhuang ZW; Xi HQ; Cai AZ; Wei B; Chen L
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jan; 23(1):38-43. PubMed ID: 31958929
[No Abstract] [Full Text] [Related]
9. Predictors of disease recurrence after curative surgery for nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNENs): a systematic review and meta-analysis.
Andreasi V; Ricci C; Partelli S; Guarneri G; Ingaldi C; Muffatti F; Crippa S; Casadei R; Falconi M
J Endocrinol Invest; 2022 Apr; 45(4):705-718. PubMed ID: 34773595
[TBL] [Abstract][Full Text] [Related]
10. Comparative outcomes of pancreatic neuroendocrine neoplasms: A population-based analysis of the SEER database.
Yang Z; Shi G
Eur J Surg Oncol; 2022 Oct; 48(10):2181-2187. PubMed ID: 35623986
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging.
Lam AK; Ishida H
Histol Histopathol; 2021 Apr; 36(4):367-382. PubMed ID: 33305819
[TBL] [Abstract][Full Text] [Related]
12. Survival comparison between primary hepatic neuroendocrine neoplasms and primary pancreatic neuroendocrine neoplasms and the analysis on prognosis-related factors.
Li MX; Li QY; Xiao M; Wan DL; Chen XH; Zhou L; Xie HY; Zheng SS
Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):538-545. PubMed ID: 30981633
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes.
Grama D; Eriksson B; Mårtensson H; Cedermark B; Ahrén B; Kristoffersson A; Rastad J; Oberg K; Akerström G
World J Surg; 1992; 16(4):632-9. PubMed ID: 1357829
[TBL] [Abstract][Full Text] [Related]
14. Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms.
Grolmusz VK; Kövesdi A; Borks K; Igaz P; Patócs A
Eur J Endocrinol; 2018 Oct; 179(4):219-228. PubMed ID: 30299890
[TBL] [Abstract][Full Text] [Related]
15. EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat?
Larghi A; Rizzatti G; Rimbaş M; Crino SF; Gasbarrini A; Costamagna G
Endosc Ultrasound; 2019; 8(4):220-226. PubMed ID: 31249164
[TBL] [Abstract][Full Text] [Related]
16. [New considerations in the surgical treatment of pancreatic neuroendocrine tumours].
Farkas G
Orv Hetil; 2013 Sep; 154(39):1565-8. PubMed ID: 24058102
[TBL] [Abstract][Full Text] [Related]
17. Calcitonin-Producing Neuroendocrine Neoplasms of the Pancreas: Clinicopathological Study of 25 Cases and Review of the Literature.
Uccella S; Blank A; Maragliano R; Sessa F; Perren A; La Rosa S
Endocr Pathol; 2017 Dec; 28(4):351-361. PubMed ID: 29063495
[TBL] [Abstract][Full Text] [Related]
18. Surgical experience with functioning pancreatic neuroendocrine tumors.
Matthews BD; Smith TI; Kercher KW; Holder WD; Heniford BT
Am Surg; 2002 Aug; 68(8):660-5; discussion 665-6. PubMed ID: 12206598
[TBL] [Abstract][Full Text] [Related]
19. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients.
Phan GQ; Yeo CJ; Hruban RH; Lillemoe KD; Pitt HA; Cameron JL
J Gastrointest Surg; 1998; 2(5):472-82. PubMed ID: 9843608
[TBL] [Abstract][Full Text] [Related]
20. Prevalence, characteristics and prognosis of MEN 1-associated glucagonomas, VIPomas, and somatostatinomas: study from the GTE (Groupe des Tumeurs Endocrines) registry.
Lévy-Bohbot N; Merle C; Goudet P; Delemer B; Calender A; Jolly D; Thiéfin G; Cadiot G;
Gastroenterol Clin Biol; 2004 Nov; 28(11):1075-81. PubMed ID: 15657529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
